Tracey G Simon1, Kathleen E Corey1, Christopher P Cannon2, Michael Blazing3, Jeong-Gun Park4, Michelle L O'Donoghue2, Raymond T Chung1, Robert P Giugliano5. 1. Liver Center, Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, United States; Harvard Medical School, Boston, MA, United States. 2. Harvard Medical School, Boston, MA, United States; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, United States. 3. Duke Clinical Research Institute, Durham, NC, United States. 4. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, United States. 5. Harvard Medical School, Boston, MA, United States; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, United States. Electronic address: rgiugliano@partners.org.
Abstract
OBJECTIVE: The nonalcoholic fatty liver disease fibrosis score (NFS) is comprised of unique metabolic risk indicators that may accurately predict residual cardiovascular (CV) risk in patients with established coronary disease and metabolic dysfunction. METHODS: We applied the NFS prospectively to 14,819 post-ACS patients randomized to ezetimibe/simvastatin (E/S) or placebo/simvastatin (P/S), in the IMPROVE-IT trial, using validated NFS cutoffs. The primary endpoint included CV death, myocardial infarction, unstable angina, revascularization or stroke. Outcomes were compared between NFS categories and treatment arms using frequency of events, KM rates and adjusted Cox proportional hazard models. The ability of the NFS to predict recurrent CV events was independently validated in 5395 placebo-treated patients enrolled in the SOLID-TIMI 52 trial. RESULTS: Among 14,819 patients enrolled in IMPROVE-IT, 14.2% (N = 2106) were high-risk (NFS > 0.67). The high-risk group had a 30% increased risk of recurrent major CV events, compared to the low-risk NFS group (HR 1.30 [1.19-1.43]; p < 0.001). Among high-risk patients, ezetimibe/simvastatin conferred a 3.7% absolute reduction in risk of recurrent CV events, compared to placebo/simvastatin (HR 0.85 [0.74-0.98]), translating to a number-needed-to-treat of 27. Similar benefit was not found in the low-risk group (HR ezetimibe/simvastatin vs. placebo/simvastatin, 1.01 [0.91-1.12]; p-interaction = 0.053). The relationship between NFS category and recurrent CV events was independently validated in patients enrolled in SOLID-TIMI 52 (HR for NFS > 0.67 vs. NFS < -1.455 = 1.55 [1.32-1.81]; p < 0.001). CONCLUSION: Stratification of cardiovascular risk by NFS identifies an independent population of patients who are at highest risk of recurrent events, and most likely to benefit from dual lipid-lowering therapy. Clinical trials.gov: NCT00202878.
RCT Entities:
OBJECTIVE: The nonalcoholic fatty liver diseasefibrosis score (NFS) is comprised of unique metabolic risk indicators that may accurately predict residual cardiovascular (CV) risk in patients with established coronary disease and metabolic dysfunction. METHODS: We applied the NFS prospectively to 14,819 post-ACS patients randomized to ezetimibe/simvastatin (E/S) or placebo/simvastatin (P/S), in the IMPROVE-IT trial, using validated NFS cutoffs. The primary endpoint included CV death, myocardial infarction, unstable angina, revascularization or stroke. Outcomes were compared between NFS categories and treatment arms using frequency of events, KM rates and adjusted Cox proportional hazard models. The ability of the NFS to predict recurrent CV events was independently validated in 5395 placebo-treated patients enrolled in the SOLID-TIMI 52 trial. RESULTS: Among 14,819 patients enrolled in IMPROVE-IT, 14.2% (N = 2106) were high-risk (NFS > 0.67). The high-risk group had a 30% increased risk of recurrent major CV events, compared to the low-risk NFS group (HR 1.30 [1.19-1.43]; p < 0.001). Among high-risk patients, ezetimibe/simvastatin conferred a 3.7% absolute reduction in risk of recurrent CV events, compared to placebo/simvastatin (HR 0.85 [0.74-0.98]), translating to a number-needed-to-treat of 27. Similar benefit was not found in the low-risk group (HR ezetimibe/simvastatin vs. placebo/simvastatin, 1.01 [0.91-1.12]; p-interaction = 0.053). The relationship between NFS category and recurrent CV events was independently validated in patients enrolled in SOLID-TIMI 52 (HR for NFS > 0.67 vs. NFS < -1.455 = 1.55 [1.32-1.81]; p < 0.001). CONCLUSION: Stratification of cardiovascular risk by NFS identifies an independent population of patients who are at highest risk of recurrent events, and most likely to benefit from dual lipid-lowering therapy. Clinical trials.gov: NCT00202878.
Authors: Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Angel Mei-Ling Chim; Ada Mei-Ling Tse; Steven Woon-Choy Tsang; Alex Yui Hui; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Wing-Yee So; Francis Ka-Leung Chan; Joseph Jao-Yao Sung; Henry Lik-Yuen Chan Journal: Am J Gastroenterol Date: 2008-07-04 Impact factor: 10.864
Authors: Roger K Schindhelm; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Coen D A Stehouwer; Robert J Heine; Michaela Diamant Journal: Atherosclerosis Date: 2006-05-08 Impact factor: 5.162
Authors: Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; David D Daly; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith Journal: J Am Coll Cardiol Date: 2016-04-01 Impact factor: 24.094
Authors: Isabelle Gerin; Laure-Alix Clerbaux; Olivier Haumont; Nicolas Lanthier; Arun K Das; Charles F Burant; Isabelle A Leclercq; Ormond A MacDougald; Guido T Bommer Journal: J Biol Chem Date: 2010-08-22 Impact factor: 5.157
Authors: Erin A Bohula; Marc P Bonaca; Eugene Braunwald; Philip E Aylward; Ramon Corbalan; Gaetano M De Ferrari; Ping He; Basil S Lewis; Piera A Merlini; Sabina A Murphy; Marc S Sabatine; Benjamin M Scirica; David A Morrow Journal: Circulation Date: 2016-07-26 Impact factor: 29.690
Authors: Erin A Bohula; Robert P Giugliano; Christopher P Cannon; Jing Zhou; Sabina A Murphy; Jennifer A White; Andrew M Tershakovec; Michael A Blazing; Eugene Braunwald Journal: Circulation Date: 2015-09-01 Impact factor: 29.690
Authors: Christopher P Cannon; Robert P Giugliano; Michael A Blazing; Robert A Harrington; John L Peterson; Christine McCrary Sisk; John Strony; Thomas A Musliner; Carolyn H McCabe; Enrico Veltri; Eugene Braunwald; Robert M Califf Journal: Am Heart J Date: 2008-09-02 Impact factor: 4.749
Authors: Kim A Eagle; Alan T Hirsch; Robert M Califf; Mark J Alberts; P Gabriel Steg; Christopher P Cannon; Danielle M Brennan; Deepak L Bhatt Journal: Crit Pathw Cardiol Date: 2009-06
Authors: Claudio Tana; Stefano Ballestri; Fabrizio Ricci; Angelo Di Vincenzo; Andrea Ticinesi; Sabina Gallina; Maria Adele Giamberardino; Francesco Cipollone; Richard Sutton; Roberto Vettor; Artur Fedorowski; Tiziana Meschi Journal: Int J Environ Res Public Health Date: 2019-08-26 Impact factor: 3.390
Authors: David Niederseer; Sarah Wernly; Sebastian Bachmayer; Bernhard Wernly; Adam Bakula; Ursula Huber-Schönauer; Georg Semmler; Christian Schmied; Elmar Aigner; Christian Datz Journal: J Clin Med Date: 2020-04-09 Impact factor: 4.241